2012 ASCO Annual Meeting Abstracts (searchable)

2012 ASCO Annual Meeting Abstracts

Welcome to the 2012 ASCO Annual Meeting abstracts home. Abstracts published in the Annual Meeting Proceedings Part I will be available on this site at 6:00 PM EDT May 16, 2012. Plenary Abstracts, Late-Breaking Abstracts, and Clinical Review Abstracts (published in the Annual Meeting Proceedings Part II) will be available at 12:01 AM EDT on the date of their presentation at the 2012 ASCO Annual Meeting.

SEARCH    2012 Abstracts       Help EXPRESS PRINT    Abstracts by Meeting Track BROWSE    Abstracts by Meeting Track

American Society of Clinical Oncology - ASCO - abstracts now available

American Society of Clinical Oncology - ASCO

ASCO '12 Abstract Dump: Cancer Stocks in Focus - TheStreet (financial)

ASCO '12 Abstract Dump: Cancer Stocks in Focus - TheStreet

.....While investors were flooded with new cancer drug data Wednesday, ASCO did hold back some of the some important and potentially stock-moving research for a more high-profile release at the meeting itself. 

Key cancer drug data that remains under wrap include results from a phase III study of Johnson & Johnson's(JNJ_) Zytiga in "pre-chemo" prostate cancer patients; a phase III study of Bayer and Onyx's regorafenib in advanced gastrointestinal stromal tumors; several Roche/Genentech(RHHBY) studies, including Avastin in ovarian cancer and TDM-1 in breast cancer (partnered with Immunogen(IMGN_)); melanoma data from GlaxoSmithKline's(GSK_) targeted drug dabrefenib; and a new targeted PD-1 immunotherapy from Bristol-Myers Squibb(BMY_).
The following pages summarize new and important cancer drug data released tonight by ASCO from research abstracts for its upcoming annual meeting.......

2012 ASCO Annual Meeting | Abstracts to be released online May 16th

2012 ASCO Annual Meeting | Abstracts

 May 16 at 6:00 PM (EDT) Abstracts released on ASCO.org*